¼¼°èÀÇ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀå(2025-2029³â)
Global Chronic Obstructive Pulmonary Disease Drugs Market 2025-2029
»óǰÄÚµå : 1777148
¸®¼­Ä¡»ç : TechNavio
¹ßÇàÀÏ : 2025³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 229 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,500 £Ü 3,521,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,000 £Ü 5,634,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀåÀº 2024-2029³â¿¡ 78¾ï 4,100¸¸ ´Þ·¯ Áõ°¡Çϰí, ¿¹Ãø±â°£ Áß CAGR·Î 6.4%ÀÇ ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù.

¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀåÀÇ ÀüüÀûÀÎ ºÐ¼®, ½ÃÀå ±Ô¸ð¡¤¿¹Ãø, µ¿Çâ, ¼ºÀå ÃËÁø¿äÀÎ, °úÁ¦, ¾à 25°³ º¥´õ¸¦ ´Ù·é º¥´õ ºÐ¼® µîÀ» °ÔÀçÇϰí ÀÖ½À´Ï´Ù.

ÇöÀçÀÇ ½ÃÀå ½Ã³ª¸®¿À, Ãֽе¿Çâ ¹× ¼ºÀå¿äÀÎ, Àüü ½ÃÀå ȯ°æ¿¡ ´ëÇÑ ÃֽŠºÐ¼®À» Á¦°øÇÕ´Ï´Ù. ½ÃÀåÀº COPD À¯º´·ü Áõ°¡, °­·ÂÇÑ ÆÄÀÌÇÁ¶óÀΰú ½Å¾à ½ÂÀÎ, º¹ÇÕÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
±âÁØ¿¬µµ 2025
Á¾·á¿¬µµ 2029
¿¹Ãø ±â°£ 2025-2029
¼ºÀå ¸ð¸àÅÒ °¡¼Ó
Àü³â´ëºñ 5.8%
CAGR 6.4%
Áõ°¡¾× 78¾ï 4,100¸¸ ´Þ·¯

º» Á¶»ç´Â ¾÷°è ÁÖ¿ä Âü¿©ÀÚµéÀÇ ÀǰßÀ» Æ÷ÇÔÇÏ¿© 1Â÷ Á¤º¸¿Í 2Â÷ Á¤º¸¸¦ °´°üÀûÀ¸·Î Á¶ÇÕÇÏ¿© ½Ç½ÃµÇ¾ú½À´Ï´Ù. ÀÌ º¸°í¼­¿¡´Â ÁÖ¿ä ±â¾÷ ºÐ¼®°ú ÇÔ²² Á¾ÇÕÀûÀÎ ½ÃÀå ±Ô¸ð µ¥ÀÌÅÍ, Áö¿ªº° ºÐ¼®¿¡ µû¸¥ ºÎ¹®, °ø±Þ¾÷ü ÇöȲÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. º¸°í¼­¿¡´Â °ú°Å µ¥ÀÌÅÍ¿Í ¿¹Ãø µ¥ÀÌÅͰ¡ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÇâÈÄ ¼ö³â°£ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) Ä¡·áÁ¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎ Áß Çϳª·Î Ä¡·áÀû Á¢±Ù¹ýÀÇ ¿¬±¸ È®´ë¸¦ ²Å°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¾à¹°Àü´Þ ÀåÄ¡ÀÇ ¹ßÀü°ú ÈíÀÔ ¿ä¹ýÀÇ È®´ë´Â ½ÃÀåÀÇ Å« ¼ö¿ä·Î À̾îÁú °ÍÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå °³¿ä

Á¦2Àå Technavio ºÐ¼®

Á¦3Àå ½ÃÀå ±¸µµ

Á¦4Àå ½ÃÀå ±Ô¸ð

Á¦5Àå ½ÃÀå ±Ô¸ð ½ÇÀû

Á¦6Àå Á¤¼º ºÐ¼®

Á¦7Àå Five Forces ºÐ¼®

Á¦8Àå ½ÃÀå ¼¼ºÐÈ­ : Á¦Ç°º°

Á¦9Àå ½ÃÀå ¼¼ºÐÈ­ : À¯Åë ä³Îº°

Á¦10Àå ½ÃÀå ¼¼ºÐÈ­ : Åõ¿© °æ·Îº°

Á¦11Àå ½ÃÀå ¼¼ºÐÈ­ : Áúȯ À¯Çüº°

Á¦12Àå °í°´ »óȲ

Á¦13Àå Áö¿ªº° »óȲ

Á¦14Àå ÃËÁø¿äÀΡ¤°úÁ¦¡¤±âȸ¡¤¾ïÁ¦¿äÀÎ

Á¦15Àå °æÀï ±¸µµ

Á¦16Àå °æÀï ºÐ¼®

Á¦17Àå ºÎ·Ï

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The chronic obstructive pulmonary disease drugs market is forecasted to grow by USD 7,841 mn during 2024-2029, accelerating at a CAGR of 6.4% during the forecast period. The report on the chronic obstructive pulmonary disease drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of copd, strong pipeline and new drug approvals, and growing demand for fixed-dose combinations.

Market Scope
Base Year2025
End Year2029
Series Year2025-2029
Growth MomentumAccelerate
YOY 20255.8%
CAGR6.4%
Incremental Value$7,841 mn

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.

Technavio's chronic obstructive pulmonary disease drugs market is segmented as below:

By Product

By Distribution Channel

By Route Of Administration

By Disease Type

By Geographical Landscape

This study identifies the expanding research in curative approaches as one of the prime reasons driving the chronic obstructive pulmonary disease drugs market growth during the next few years. Also, advances in drug delivery devices and expansion of inhalation therapies will lead to sizable demand in the market.

The report on the chronic obstructive pulmonary disease drugs market covers the following areas:

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic obstructive pulmonary disease drugs market vendors that include AstraZeneca Plc, Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., CHIESI Farmaceutici SpA, Cipla Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., Innoviva Inc., Lupin Ltd., Merck and Co. Inc., Novartis AG, SHIONOGI Co. Ltd., Sumitomo Pharma Co. Ltd., Teva Pharmaceutical Industries Ltd., Theravance Biopharma Inc., Viatris Inc., and Phillips Medisize. Also, the chronic obstructive pulmonary disease drugs market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.

Table of Contents

1 Executive Summary

2 Technavio Analysis

3 Market Landscape

4 Market Sizing

5 Historic Market Size

6 Qualitative Analysis

7 Five Forces Analysis

8 Market Segmentation by Product

9 Market Segmentation by Distribution Channel

10 Market Segmentation by Route of Administration

11 Market Segmentation by Disease Type

12 Customer Landscape

13 Geographic Landscape

14 Drivers, Challenges, and Opportunity/Restraints

15 Competitive Landscape

16 Competitive Analysis

17 Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â